These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37694786)

  • 21. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
    Zawar LR; Bari SB
    Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanosuspensions: Enhancing drug bioavailability through nanonization.
    Chavhan R
    Ann Pharm Fr; 2024 Jun; ():. PubMed ID: 38945393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fabrication of Stable Apigenin Nanosuspension with PEG 400 as Antisolvent for Enhancing the Solubility and Bioavailability.
    Xu R; Jiang C; Zhou L; Li B; Hu Y; Guo Y; Xiao X; Lu S
    AAPS PharmSciTech; 2021 Dec; 23(1):12. PubMed ID: 34881399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
    Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
    Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
    Sun W; Ni R; Zhang X; Li LC; Mao S
    Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs.
    Khan KU; Minhas MU; Badshah SF; Suhail M; Ahmad A; Ijaz S
    Life Sci; 2022 Feb; 291():120301. PubMed ID: 34999114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics.
    Bhalani DV; Nutan B; Kumar A; Singh Chandel AK
    Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
    Kassem MAA; ElMeshad AN; Fares AR
    AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies - Development of particle design method.
    Niwa T; Miura S; Danjo K
    Int J Pharm; 2011 Feb; 405(1-2):218-27. PubMed ID: 21167922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation.
    Yadav SK; Mishra S; Mishra B
    AAPS PharmSciTech; 2012 Dec; 13(4):1031-44. PubMed ID: 22893314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
    Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
    Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
    Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-Based Nanosystem As Intelligent Carriers for Versatile Drug Delivery Applications.
    Harshita ; Barkat MA; Das SS; Pottoo FH; Beg S; Rahman Z
    Curr Pharm Des; 2020; 26(11):1167-1180. PubMed ID: 32026769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor.
    Na YG; Pham TMA; Byeon JJ; Kim MK; Han MG; Baek JS; Lee HK; Cho CW
    Int J Pharm; 2020 May; 581():119287. PubMed ID: 32243963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of recent patents on nanosuspension.
    Modh N; Mehta D; Parejiya P; Popat A; Barot B
    Recent Pat Drug Deliv Formul; 2014; 8(2):144-54. PubMed ID: 24758487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
    Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
    Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug delivery strategies for poorly water-soluble drugs.
    Fahr A; Liu X
    Expert Opin Drug Deliv; 2007 Jul; 4(4):403-16. PubMed ID: 17683253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies.
    Zhang X; Li LC; Mao S
    Curr Pharm Des; 2014; 20(3):388-407. PubMed ID: 23651400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.
    van Hoogevest P; Liu X; Fahr A
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1481-500. PubMed ID: 21895540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
    Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
    Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.